SCHEMBL9912178

SCHEMBL9912178

CCn1c(=O)c2cccn2c2cc(OC)ccc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.53
▸ TP53 P04637 7/20 0.53
▸ POLB P06746 2/20 0.53
▸ RXFP1 Q9HBX9 4/20 0.50
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ LMNA P02545 3/20 0.46
▸ GRIK2 Q13002 2/20 0.46
▸ GRIK1 P39086 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ GRM2 Q14416 1/20 0.43
▸ PTGER4 P35408 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9912175 0.94 TP53 (0.53) MAPTTP53POLBRXFP1MEN1
SCHEMBL15043471 0.84 POLB (0.48) MAPTTP53POLBRXFP1MEN1
SCHEMBL21755744 0.83 POLB (0.52) MAPTTP53POLBRXFP1LMNA
SCHEMBL15043478 0.81 POLB (0.51) MAPTTP53POLBRXFP1MEN1
SCHEMBL9912167 0.80 LMNA (0.60) MAPTTP53POLBRXFP1MEN1
SCHEMBL9910991 0.75 MAPT (0.45) MAPTTP53POLBRXFP1MEN1
SCHEMBL21755743 0.72 ADRB2 (0.75) MAPTTP53POLBLMNA
SCHEMBL20551994 0.72 OPRK1 (0.53) MAPTTP53POLBLMNA
SCHEMBL9912169 0.71 GABRA5 (0.58) MAPTTP53POLBRXFP1MEN1
SCHEMBL24120919 0.71 TP53 (0.70) MAPTTP53POLBRXFP1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120141471-A1 Methods of Inhibiting Metastasis from Cancer Alliance Discovery, Inc. 2012-06-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120141471-A1 Methods of Inhibiting Metastasis from Cancer CX3CR1, CXCR3, CCR5 MAPT 4217/4885TP53 817/4885POLB 4243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback